The Clinical Immunology Service provides a unique interface between the University's substantial scientific expertise in immunology and the main clinical areas for application in clinical academia and NHS practice. The service is a nidus for successful, productive (see references and teaching) interaction with clinical academics (nephrology, rheumatology, haematology, hepatology) and basic research groups in the Institute of Biomedical Research, School of Cancer Sciences and Biosciences.
Central laboratory analysis and member trial management group for Phase 3 UK myeloma trials for 23 years ( MRC 6, 7, 8, 9, 10, 11). These trials have helped formulate world opinion on the relative efficacy of different combinations of anti-myeloma therapy and supportive care. Chief Investigatior for TEAMM that assesses antibiotic prophylaxis and health care associated infections in myeloma. Management of renal failure in myeloma has been advanced by MERIT and is being furthered in OPTIMAL.
Development of diagnostic tests includes helping develop the first clinical test for serum free light chains (sflc) launched in 2002. Demonstrated clinical utility and validity of the sflc test retrospectively and then prospectively in MRC Myeloma 9th – 11th trials and in MERIT. This first sflc test is recommended by international guidelines to stratify and manage patients with plasma cell dyscrasias and use of the test has been disseminated by Binding Site across 90 countries and increased to 6 million tests per year. Mark has developed a second generation of the test which is being commercialised by University spin out company, Serascience, providing improved laboratory and unique point of care versions of the test.
A longstanding Leukaemia lymphoma Research funded collaboration with Prof. Chris Bunce into blood cancers is translating into the clinic, enabling completion of trials of novel biological therapies for leukaemia / lymphoma with further trials in progress in the West Midlands and in Africa. This Programme has just been refunded along with Dr Farhat Khanim as an LLR Programme - Aldo-keto reductases (AKRs), BaP therapy and drug redeployment strategies for accelerating therapy development for haematological cancers.
Collaborative work with Sports and Exercise Medicine has developed an international reputation for the effect of physical and mental stress on response to vaccination and other parameters of immune function